Not FDA Approved Well-Established
Mechanism of Action
GHRP-2 is a synthetic hexapeptide that stimulates growth hormone release by acting as an agonist at the ghrelin receptor (GHSR-1a). It mimics endogenous ghrelin with more potent GH-releasing effects relative to appetite stimulation, making it the most clinically validated GHRP.
Potential Benefits
Approved in Japan for GH deficiency diagnostic testing (pralmorelin) More potent GH release than GHRP-6 with less appetite stimulation Well-characterized dose-response in multiple clinical studies Increases IGF-1 levels downstream of GH elevation Moderate appetite stimulation (less than GHRP-6, more than Hexarelin) Subcutaneous bioavailability estimated at 70-80%
Known Side Effects
Injection site reactions (redness, discomfort) — transient Headache — mild to moderate Transient cortisol elevation — dose-dependent Mild water retention — usually transient Nausea (less common) Increased prolactin (transient)
Not FDA Approved Well-Established
What is GHRP-2?
GHRP-2 (pralmorelin) is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW 817.9 Da) that stimulates growth hormone secretion by acting as an agonist at the ghrelin receptor (GHSR-1a). It is unique among growth hormone-releasing peptides (GHRPs) in that it received regulatory approval in Japan in 2003-2004 for diagnostic testing of GH deficiency, making it the most clinically validated compound in the GHRP class.
GHRP-2 is more potent than GHRP-6 for GH release but less potent than Hexarelin. Its appetite stimulation is moderate — present but significantly less pronounced than GHRP-6. It has a half-life of approximately 1-2 hours following subcutaneous administration with an estimated bioavailability of 70-80%. GHRP-2 has never received FDA approval in the United States and is prohibited by WADA for athletic use since 2008.
Mechanism of Action
GHRP-2 works by directly binding to the GHSR-1a (ghrelin receptor) in pituitary somatotrophs, triggering growth hormone release. This mimics the action of endogenous ghrelin but with more potent GH-releasing effects relative to appetite stimulation.
Key targets include the GHSR-1a receptor for GH secretion, the GH axis for downstream IGF-1 elevation, NPY/AgRP hypothalamic neurons for appetite effects, and transient cortisol elevation through dose-dependent pituitary stimulation. GHRP-2 does not share Hexarelin's CD36 cardiac binding, which means less cardiac effect but also less potential cardioprotection.
The potency hierarchy among GHRPs places GHRP-2 as the second most potent GH releaser (behind Hexarelin) and second for appetite stimulation (behind GHRP-6), giving it a balanced profile.
Clinical Evidence
Human Studies
GHRP-2 has the most substantial clinical trial history of any GHRP, with Phase II/III trials completed in Japan and multiple studies in the US and Europe.
Japanese Phase III Diagnostic Trial (2004): Multi-center RCT (N=120) established that pralmorelin at 1 mcg/kg IV produces GH response >15 mcg/L in healthy subjects and <15 mcg/L in severe GHD, validating the diagnostic cutoff (PMID: 15230633).
GH Stimulation Test Validation (2002): Clinical trial (N=85) validated pralmorelin as a safe, well-tolerated GH stimulation test (PMID: 12030918).
Phase II Short Stature Trial: Kaken Pharmaceutical's internal study showed increased growth velocity in children with pituitary dwarfism, though it was never marketed.
Appetite/Hunger Study: Randomized crossover (N=12 healthy men) at 100 mcg/kg subcutaneous showed significant food intake increase versus placebo, though less pronounced than GHRP-6.
Overall, GHRP-2 has approximately 15-20 human studies, 3-5 RCTs, and the only regulatory approval of any GHRP worldwide.
Preclinical Evidence
Animal studies have demonstrated anti-inflammatory effects in arthritic rat models (PMID: 15507538), GI contractile activity modulation, and consistent GH-axis activation across species.
Drug Interactions & Contraindications
Glucocorticoids are documented to blunt the GH response to GHRP-2. Somatostatin analogs directly antagonize its GH-releasing action and are considered contraindicated for concurrent use. Theoretical interactions exist with GHRH analogs (additive GH release), IGF-1/growth hormone (additive effects requiring IGF-1 monitoring), and diabetes medications (IGF-1 may affect glucose control).
GHRP-2 is contraindicated in active malignancy (GH/IGF-1 elevation could theoretically promote tumor growth) and during pregnancy or breastfeeding. No formal drug interaction studies have been conducted in humans.
Safety & Side Effects
From human trials, commonly reported effects (10% or more of subjects) include injection site reactions, headache, transient cortisol elevation, and mild water retention. Less common effects include nausea, flushing, and transient prolactin elevation.
Theoretical concerns include cardiovascular effects (less than Hexarelin due to absence of CD36 cardiac binding), cancer risk from GH/IGF-1 elevation, and glucose metabolism effects in diabetic patients. The longest human trials were 6-12 months in Japanese pediatric studies — no multi-year adult safety data exists.
Honest Bottom Line
GHRP-2 (pralmorelin) represents the most clinically validated GHRP with actual regulatory approval in Japan for diagnostic use and 3-5 RCTs in humans, placing it at Tier 3. It is more potent than GHRP-6 for GH release while producing less appetite stimulation. However, it has never received FDA approval for any indication in the United States, no active clinical trials are underway as of 2026, and it remains banned by WADA. Patients considering GHRP-2 should understand they are using a compound with moderate human evidence — better than most peptides — but no FDA-approved therapeutic indication in the US.